The Board of Directors of Vivesto AB ("Vivesto" or the "Company") has resolved to propose that the Annual General Meeting on 7 May 2026 resolves on a reverse share split, whereby one hundred (100) existing shares are consolidated into one (1) new share (the "Reverse Share Split"). In accordance with the proposal, the Board of Directors shall be authorised to determine the record date for the Reverse Share Split. The Board of Directors further proposes that the Annual General Meeting resolves on reduction of the share capital. The proposals will be presented in detail in the notice of the Annual General Meeting, which will be published through a separate press release.
In order to achieve an appropriate number of shares for the Company, the Board of Directors has resolved to propose that the Annual General Meeting resolves on the Reverse Share Split and to authorise the Board of Directors to determine a record date for the implementation of the Reverse Share Split.
The Reverse Share Split entails that one hundred (100) existing shares are consolidated into one (1) new share. The total number of shares and votes in the Company would thereby decrease from 1,107,136,910 to 11,071,369. Following the completion of the Reverse Share Split, the quota value will amount to SEK 1 per share, provided that the Annual General Meeting also resolves on reduction of the share capital in accordance with the Board of Directors' separate proposal to the Annual General Meeting regarding resolution on amendments of the articles of association and reduction of the share capital.
If a shareholder's holding of shares does not correspond to a full number of new shares, i.e. is not evenly divisible by 100, the excess shares will pass to the Company on the record date for the Reverse Share Split. The excess shares will thereafter be sold by a securities institution engaged by the Company, whereby concerned shareholders will receive their share of the sales proceeds. Further information regarding the procedure for the Reverse Share Split will be published by the Company in connection with the Board of Directors' determination of the record date.
The Board of Directors has also resolved to propose that the Annual General Meeting resolves on a reduction of the share capital by SEK 99,642,322, from SEK 110,713,691 to SEK 11,071,369. As a result of the rights issue of shares resolved by the Board of Directors on 20 November 2025 and approved by the Extraordinary General Meeting on 22 December 2025, and the subsequent directed share issue to the guarantors in the rights issue, the share capital has increased to a level which cannot be considered appropriate in relation to the Company's operations and actual capital needs. The purpose of the reduction is allocation to unrestricted equity, meaning that the total equity is not affected. The reduction is proposed to be effected without redemption of shares.
A notice of the Annual General Meeting will be published through a separate press release.
For More Information:
Erik Kinnman, Chief Executive Officer
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com
About Vivesto AB
Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.
Vivesto's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.
